- Home
- STTK vs CUPR Comparison
STTK vs CUPR Comparison
Compare STTK & CUPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CUPR
- Stock Information
- Founded
- STTK 2016
- CUPR 2019
- Country
- STTK United States
- CUPR Singapore
- Employees
- STTK N/A
- CUPR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CUPR
- Sector
- STTK Health Care
- CUPR
- Exchange
- STTK Nasdaq
- CUPR NYSE
- Market Cap
- STTK 38.4M
- CUPR 43.2M
- IPO Year
- STTK 2020
- CUPR 2025
- Fundamental
- Price
- STTK $0.77
- CUPR $7.83
- Analyst Decision
- STTK Hold
- CUPR
- Analyst Count
- STTK 4
- CUPR 0
- Target Price
- STTK $3.00
- CUPR N/A
- AVG Volume (30 Days)
- STTK 229.3K
- CUPR 569.2K
- Earning Date
- STTK 08-04-2025
- CUPR 01-01-0001
- Dividend Yield
- STTK N/A
- CUPR N/A
- EPS Growth
- STTK N/A
- CUPR N/A
- EPS
- STTK N/A
- CUPR N/A
- Revenue
- STTK $4,606,000.00
- CUPR $35,406.00
- Revenue This Year
- STTK N/A
- CUPR N/A
- Revenue Next Year
- STTK N/A
- CUPR N/A
- P/E Ratio
- STTK N/A
- CUPR N/A
- Revenue Growth
- STTK 69.65
- CUPR N/A
- 52 Week Low
- STTK $0.69
- CUPR $3.51
- 52 Week High
- STTK $4.51
- CUPR $8.15
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- CUPR N/A
- Support Level
- STTK $0.73
- CUPR N/A
- Resistance Level
- STTK $0.92
- CUPR N/A
- Average True Range (ATR)
- STTK 0.07
- CUPR 0.00
- MACD
- STTK 0.01
- CUPR 0.00
- Stochastic Oscillator
- STTK 20.80
- CUPR 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.